Immix Biopharma, Inc.
IMMXHealthcare|Biotechnology|US
$8.06
+0.86 (+11.94%)
DCF Value
$2.66
Tangible Book / Share
$3.59
Cash / Share
$3.64
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Light Chain (AL) Amyloidosis | P1P2 | Active | 45 | Open-label | NXC-201 CAR-T |
| NCT07709715 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis | Light Chain (AL) Amyloidosis | P3 | Not Yet Recruiting | 260 | RCT, Open-label | NXC-201, Dara-CyBorD |
| NCT05840835 Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Unknown | 60 | Open-label | IMX-110 combined with Tislelizumab |
| NCT03382340 IMX-110 in Patients With Advanced Solid Tumors | Solid Tumor, Adult, Advanced Solid Tumors | P1P2 | Unknown | 70 | Open-label | Imx-110 |